Bristol Myers Squibb
Tracked across 32 events · 685 articles · First seen Sep 26, 2025 · Last active Aug 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: BMS is deploying the most powerful Nvidia AI infrastructure in life sciences, aiming to compress drug discovery timelines and improve pipeline success rates. The investment builds on a three-year collaboration and is expected to enhance its competitive position in AI-driven R&D.
Jul 20, 2026 · 14 articles
Business
Impact: Bristol Myers Squibb is the target of the potential merger, which would provide it with a significant premium and access to AstraZeneca's pipeline. Its shares have risen 43% in the past year, and the deal could further boost its valuation.
Aug 02, 2026 · 60 articles
Business
Bristol Myers Squibb (BMS) announced on August 10, 2026, a $2.3 billion investment to build a new multi-modal manufacturing campus in United States — Houston, United States — Texas. The 600,000-square-foot facility, located at Generation…
Impact: Bristol Myers Squibb is the primary investor, committing $2.3 billion to build a new manufacturing campus in United States — Houston. This investment is part of its $40 billion U.S. expansion plan and is expected to enhance its manufacturing capabilities and support future drug production.
Aug 10, 2026 · 20 articles
Business
Impact: Bristol Myers Squibb is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Tech
Impact: Bristol Myers Squibb>>>'s immunotherapies Opdivo and Yervoy are mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Jun 02, 2026 · 45 articles
Tech
Impact: Founding and major contributing member; provides pharmaceutical expertise and data.
Jul 13, 2026 · 6 articles
Business
Impact: Bristol Myers Squibb divests CeeNU in Canada, a minor portfolio adjustment.
Jul 15, 2026 · 8 articles
Tech
Impact: Bristol Myers Squibb is jointly developing pumitamig with BioNTech, which is being used in the clinical trial collaboration with Boehringer Ingelheim.
Apr 09, 2026 · 6 articles
Regulatory
Impact: Bristol Myers Squibb is one of the major drugmakers that has reached pricing agreements with the Donald Trump administration to avoid the new tariffs.
Apr 02, 2026 · 23 articles
Business
Impact: Bristol Myers Squibb is a partner of Optellum in the US, supporting the commercial momentum of Optellum's AI solutions in lung cancer care.
Jun 04, 2026 · 6 articles
Business
Impact: Bristol Myers Squibb is participating in the Kinaxis conference as a speaker, sharing insights on navigating disruption and improving operational outcomes in supply chain management.
May 28, 2026 · 6 articles
Business
Impact: Bristol Myers Squibb had an executive, Anvita Karara, recognized with an Ignite Leadership Award for driving enterprise-wide AI transformations within the company.
Jun 25, 2026 · 8 articles
Tech
Cumulus Neuroscience announced the publication of final results from its CNS-102 study in Scientific Reports, demonstrating that its at-home NeuLogiq Platform is feasible, well tolerated, and highly usable for multimodal cognitive assessment in people living…
Impact: Bristol Myers Squibb is a consortium member. The publication may influence its approach to cognitive endpoints in neurodegenerative disease trials.
Aug 18, 2026 · 6 articles
Regulatory
Replimune Group, a biotechnology company, faces multiple securities class action lawsuits filed by several law firms, including Pomerantz LLP, Bronstein, Gewirtz & Grossman, LLC, Levi & Korsinsky, and Schall Brown & Schwartz LLP, on behalf…
Impact: Bristol Myers Squibb's drug Opdivo is part of the combination therapy in Replimune's BLA. The rejection may have minor negative implications for BMS, but it is not a primary defendant.
Jul 29, 2026 · 65 articles
Domestic
Impact: Bristol Myers Squibb, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Business
A wave of strong corporate earnings, particularly from AI-related companies, drove major U.S. stock indexes to record highs in early August 2026. Microsoft, Amazon (company), Palantir, and Caterpillar reported better-than-expected results, easing investor concerns about…
Impact: Reportedly in merger talks with AstraZeneca, which could create a $400 billion drugmaker.
Jul 14, 2026 · 280 articles
Business
Impact: Bristol Myers Squibb is a pharmaceutical company that participates in the OpenFold consortium, benefiting from access to AI-enabled tools for drug discovery.
Jun 10, 2026 · 9 articles
Regulatory
Impact: Bristol Myers Squibb supported Gilead's appeal, gaining from the precedent that reduces innovation-related legal risks.
Aug 03, 2026 · 6 articles
Business
On August 10, 2026, Novo Nordisk and Amazon — Amazon Web Services (AWS) announced a strategic partnership to accelerate drug discovery and modernize operations through agentic AI and cloud technologies. The agreement establishes AWS as…
Impact: Bristol Myers Squibb is mentioned as another pharmaceutical company partnering with AI firms, but this event does not directly impact it.
Aug 10, 2026 · 7 articles
Business
Impact: Bristol Myers Squibb is a drug sponsor engaged with Cellares' Cell Shuttle platform and has a $380 million global manufacturing agreement with Cellares, reserving commercial-scale capacity.
Jun 15, 2026 · 6 articles
Regulatory
Impact: Bristol Myers Squibb has a presence in Hyderabad with R&D and capability centers, contributing to India — Telangana's life sciences ecosystem.
Jan 21, 2026 · 6 articles
Business
Impact: Bristol Myers Squibb originally licensed bempikibart to Q32 Bio; no direct impact from this event.
Jul 13, 2026 · 6 articles
Business
Impact: Bristol Myers Squibb is mentioned as a prior acquirer in the sector, highlighting the trend of radiopharmaceutical consolidation.
Aug 03, 2026 · 7 articles
Business
AstraZeneca announced on August 17, 2026, that it is discontinuing the Phase III EVOLVE-Lung02 trial of volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC). The decision followed a recommendation from an…
Impact: Bristol Myers Squibb was mentioned in the context of brief merger speculation involving AstraZeneca, which triggered investor backlash but is not directly part of this event.
Aug 17, 2026 · 20 articles
Business
Impact: Dieter Weinand has led business operations for companies including Bristol Myers Squibb.
Apr 07, 2026 · 9 articles
Business
Impact: Bristol Myers Squibb acquired the lead asset from Goldfinch Bio, a company founded by Anna Greka>>>.
Jun 03, 2026 · 6 articles
Business
Impact: Bristol-Myers Squibb is mentioned as a customer of Syngene, but the event has no direct impact on the company.
Jul 01, 2026 · 6 articles
+ 2 more events
View on Dashboard
100
Bristol Myers Squibb announced investmentBristol Myers Squibb...
90
Bristol Myers Squibb selected United States — Houston United States — HoustonBristol Myers Squibb...
80
Bristol Myers Squibb committed to investBristol Myers Squibb...
80
AstraZeneca explored merger Bristol Myers SquibbAI earnings drive record...
70
Bristol Myers Squibb held merger talks AstraZenecaAI earnings drive record...
70
Bristol Myers Squibb will create jobsBristol Myers Squibb...
60
United States — Texas granted incentive Bristol Myers SquibbBristol Myers Squibb...
40
Greg Abbott praised investment Bristol Myers SquibbBristol Myers Squibb...
30
Bristol Myers Squibb struck deal with Anthropic AnthropicNovo Nordisk AWS AI Drug...
ERGEN INTELLIGENCE
Track Bristol Myers Squibb live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard